media – Page 178 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

New report urges UK policymakers to take urgent action on declining child health

The report includes five recommendations for the government to address these issues The Academy of Medical Sciences has published a new report that highlights evidence of declining health among children under five years in the UK and has called on policymakers to take urgent action. The new report highlights that children’s health has been overlooked in policy, the health service and research from pre-conception through pregnancy to the first five years of life. Written by several child health experts, the new report, Prioritising Early Childhood to Promote the Nation’s Health, Well-being and Prosperity, warns the UK government of major health issues including infant mortality, obesity and tooth decay and highlights the economic prosperity of children’s health, which is estimated to cost at least £16bn a year. According to the report, which involved perspectives from parents and carers, infant survival rates are worse than in 60% of similar countries and, between ...
- Source: drugdu
- 150
- February 27, 2024
NIHR awards over £20m to eight new global health research projects

The projects will focus on healthcare in LMICs in the event of extreme weather The National Institute for Health and Care Research (NIHR) has awarded over £20m to eight new global health research projects to strengthen health service delivery and resilience in low- and middle-income countries (LMICs), specifically in the context of extreme weather events. Extreme weather events due to climate change, including tropical storms, droughts and floods, are increasingly common and are “a real threat to health across the globe – driving natural disasters… and disrupting people’s access to healthcare in many countries,” said Professor Lucy Chappell, chief executive officer, NIHR. Over the next three to five years, awards ranging between £1m and £3m will be awarded through the NIHR’s Research and Innovation for Global Health Transformation (RIGHT) Programme to fund health research in LMICs. The new projects follow the endorsement of the Declaration of Climate and Health by ...
- Source: drugdu
- 154
- February 27, 2024
Subsidiary of Zhengda Tianqing Passed FDA’s On-site Inspection with “Zero Defect” for Three Consecutive Times

Recently, Lianyungang Runzhong Pharmaceutical, a wholly-owned subsidiary of Zhengda Tianqing Pharmaceutical Group, passed the on-site inspection of the U.S. Food and Drug Administration (FDA) with “zero defects”, which means that the company’s quality management system has once again been recognized by international authoritative drug regulatory agencies. Previously, Runzhong Pharmaceutical has passed the FDA on-site inspection with zero defects twice in 2014 and 2018. FDA is recognized as one of the most authoritative and strict agencies in the world for drug quality supervision.2024 From January 22 to January 26, FDA conducted pre-approval inspections on two antineoplastic products of Runzhong Pharmaceuticals, as well as supervisory inspections on four products commercialized in the U.S. market, namely, aminophosine, fosaprepitant dimeglumine, phosphonate, and fulvestrant. At the final meeting on January 26, the inspector announced on-site that R&Z passed the inspection with zero defects. It is understood that during this on-site inspection, the FDA inspector conducted ...
- Source: drugdu
- 97
- February 27, 2024
Dupixent® Receives Another FDA Priority Review for Chronic Obstructive Pulmonary Disease (COPD) with Type 2 Inflammation

Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of Dupixent (dupliximab) for a sixth potential indication as a supplemental biologic. Sanofi announced today that the U.S. Food and Drug Administration (FDA) has granted priority review of the Supplemental Biologics License Application (SBLA) for the sixth potential indication for dabigatran (duplizumab), an add-on maintenance treatment for adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The FDA approval is expected on June 27, 2024. China has also submitted a marketing authorization application and received acceptance from the Center for Drug Evaluation (CDE) of the State Drug Administration (SDA). Data from two Phase III clinical trials (BOREAS and NOTUS) supporting this SBLA and other applications globally evaluated the efficacy and safety of Dupixent in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation who are smokers or have a history of ...
- Source: drugdu
- 178
- February 27, 2024
February 23, 2024

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), which was approved for use in combination with dexamethasone to treat certain patients with multiple myeloma. The agency determined the following grounds for withdrawal were met: (1) the confirmatory study conducted as a condition of accelerated approval did not confirm Pepaxto’s clinical benefit, and (2) the available evidence demonstrates that Pepaxto is not shown to be safe or effective under its conditions of use. The final decision was issued by the FDA’s Center for Biologics Evaluation and Research Director Peter Marks, M.D., Ph.D., as the Commissioner’s designee. The decision is effective immediately. The FDA plans to publish a Federal Register notice announcing the availability of today’s decision and remove Pepaxto from the Orange Book. It is the FDA’s ...
- Source: drugdu
- 86
- February 27, 2024
The first patient has been dosed, and the latest progress of Abbisko Therapeutics’s new generation EGFR Exon20ins inhibitor ABSK112

On February 23, 2024, Abbisko Therapeutics announced that its independently developed new-generation EGFR Exon20ins inhibitor ABSK112 has completed the first patient administration in its Phase I clinical trial for non-small cell lung cancer (NSCLC). Previously, ABSK112 has obtained clinical research licenses from China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), and is conducting Phase I clinical trials simultaneously in China and the United States. ABSK112 is a new generation of EGFR Exon20ins oral inhibitor with high activity, high selectivity and brain entry properties. Compared with the previous generation of EGFR Exon20ins inhibitors that have been on the market or entered clinical trials, ABSK112 has demonstrated better brain entry properties, high selectivity against wild-type EGFR, and broader Exon20ins mutation coverage in preclinical studies. It has shown excellent in vivo efficacy in multiple mouse tumor models with EGFR Exon20ins mutations. It has the potential to obtain ...
- Source: drugdu
- 98
- February 27, 2024
【EXPERT Q&A】What is the FDA registration review process for medical devices?

Drugdu.com expert’s response: The FDA registration review process for medical devices involves the following key steps: 1.Determine Product Classification: Firstly, the classification of the medical device needs to be determined, i.e., identifying which category it falls under in the FDA’s classification system. FDA categorizes medical devices into three classes: Class I, Class II, and Class III. The registration review process and requirements may vary depending on the device’s classification. 2.Prepare Registration Application: Prepare a comprehensive registration application package according to FDA requirements, including product description, technical specifications, design files, clinical trial data (if applicable), quality management system documentation, manufacturing process documentation, etc. 3.Submit Registration Application: Submit the complete registration application package to the FDA. Typically, this is done through the FDA’s electronic registration system, the FDA Unified Registration and Listing System (FURLS). 4.Registration Review: The FDA reviews the submitted registration application. During the review process, the FDA may request further information ...
- Source: drugdu
- 161
- February 26, 2024
Simple Blood Test Quickly and Accurately Diagnoses Potentially Life-Threatening Inflammatory Disease

Sarcoidosis, a chronic inflammatory condition characterized by small lumps known as granulomas in the lungs and other organs, remains a medical mystery with its exact cause yet to be understood. Current theories suggest it might be an immune disorder triggered by specific antigens, usually foreign substances that provoke an immune response. Diagnosing sarcoidosis is currently a complex process that typically involves tissue removal and testing, accompanied by additional screenings to exclude other conditions like tuberculosis or lung cancer. Now, researchers have developed a tool that uses a simple blood test to rapidly and inexpensively diagnose sarcoidosis, potentially reducing the need for more invasive diagnostic techniques presently used to detect the disease. In a research project supported by the National Institutes of Health (NIH, Bethesda, MD, USA), researchers at Wayne State University (Detroit, MI, USA) set out to identify antigens and determine which might be linked to sarcoidosis. They collected lung ...
- Source: drugdu
- 197
- February 26, 2024
State-Of-The Art Techniques to Probe Bacterial Cause Of Deadly Strep A Infections

Annually, a staggering half a million people, including numerous children and young individuals, succumb to serious infections caused by the group A streptococcal (Strep A) bacteria globally. Strep A is highly transmissible and spreads from person to person mostly via the respiratory route from sore throats. Strep A is typically known for causing sore throats and skin infections in younger children. However, both groups are very susceptible to the invasive form of the infection. In rare cases, it can lead to more severe conditions like sepsis and toxic shock if the bacteria invade the bloodstream or tissue. A particularly alarming consequence of repeated Strep A infections is the autoimmune-induced damage to heart valves, termed rheumatic heart disease (RHD). RHD affects approximately 50 million people worldwide, predominantly in middle- and low-income countries. Currently, there is no vaccine available for Strep A. The development of immunity to Strep A over time, including ...
- Source: drugdu
- 166
- February 26, 2024
Study Finds Parkinson Disease Drug Nearly Matches Wegovy in Weight Loss Effects

Don Tracy, Associate Editor Early-stage trial results indicate that NLRP3 inflammasome inhibitors were able to achieve nearly the same weight loss as Wegovy while also reducing inflammatory biomarkers linked to heart disease. Results from an early-stage study found that a novel therapy for Parkinson disease produced nearly the same weight loss effect as the blockbuster GLP-1 receptor agonist Wegovy (semaglutide), while also lowering inflammatory biomarkers associated with heart disease. In a study published by The Journal of Pharmacology and Experimental Therapeutics, researchers for NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, aimed to discover the efficacy of the investigational NLRP3 inflammasome inhibitors NT-0249 and NT-0796 in reversing obesity-related complications. They focused on systemic inflammation and astrogliosis in the hypothalamus. To find a sufficient answer, the study relied on diet-induced obesity (DIO) mouse models treated with NT-0249 and NT-0796 to assess their impact on obesity reversal. ...
- Source: drugdu
- 187
- February 26, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.